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Online UV Imaging of API-excipient mixtures during 
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Elke Prasad, Gavin H. Halbert 
Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow 
Introduction 
The Sirius SDI has been shown to provide real-time information of the 
dissolution process at the surface of drug compacts (1, 2). Here, the 
release mechanism of Carvedilol (CAR), a BCS class II drug, with either 
HPMC or Eudragit EPO was investigated. 
 
Materials and Methods 
Compacts of Carvedilol (CAR), HPMC (Benecel E3, Ashland) and 
Eudragit EPO (EPO) (Evonik) and mixtures thereof were and exposed to 
simulated gastric fluid (SGF, pH 1.2) in a flow cell suitable for UV 
imaging.  Dissolution assays for CAR only compacts were also performed 
using SGF buffer containing 1% and 5% of HPMC or EPO, respectively. 
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Figure 1. Schematic side view of the SDI system. 
Results 
To assess dissolution of polymer only compacts only, analysis was 
performed using a visible wavelength range. HPMC showed swelling 
behaviour, whereas EPO did not (Figure 3). 
Physical mixtures of CAR with HPMC showed a steady release of the drug, whereas 
PL[WXUHVZLWK(32VKRZHGGUXJUHOHDVHLQVPDOOµEXUVWV¶)LJXUH7KHSUHVHQFHRI
polymer increased the amount of drug released. 
Figure 3a: Eudragit EPO at 550nm. Figure 3b: HPMC at 550nm. 
Figure 4a: Physical mixture CAR-HPMC 
at 280nm. 
Figure 4b: Physical mixture CAR-EPO 
at 280nm. 
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Figure 5: Physical mixture sample mass released 
at 280nm. 
Discussion and Conclusion 
UV imaging was used to characterise dissolution behaviour of 
&$5LQWKHSUHVHQFHRIH[FLSLHQWVVKRZLQJµEXUVWV¶RI&$5
released from physical mixtures with Eudragit EPO during the 
dissolution assay, whereas HPMC showed a steady 
swelling/erosion release behaviour. 
In experiments with excipient modified SGF buffers, only 1% 
EPO showed an increase in drug dissolution. The altered 
viscosities/densities of modified buffers, may decrease the 
concentration gradient in the buffer system and therefore 
reducing dissolution rates. It may also indicate that the 
interaction between the polymer and drug requires a non-
hydrated polymer, or a higher polymer concentration at the 
drug surface in concurrence with a low viscosity buffer to 
drive dissolution via a concentration gradient. 
 
Future Work  
Further characterisation of compact surface are required to 
determine the impact of polymers on release behaviour of 
CAR. Rheological assessment of modified dissolution buffers.  
Analysis of processed formulations including Raman 
monitoring of potential phase transitions during the dissolution 
assay.  
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Buffer modifications 
Buffer containing 1% EPO, improved the diffusion behaviour of CAR 
over media only and other buffers containing excipients. However, an 
increase to 5% EPO resulted in a diffusion inhibiting effect. This may 
be due to the higher viscosity of the dissolution medium.  
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Figure 6: Buffer modifications, sample mass released at 280nm. 
